-

Beyond survival: The road ahead for patients
November 7, 2026“Cancer survivorship starts at the time of diagnosis, through the balance of an individual’s life. GU cancer survivors include...
-

Germline-somatic interplay and testing pathways: What matters most?
November 7, 2026What matters in germline-somatic interplay and testing pathways in precision oncology? Plenary Session 7 “Familial cancers: molecular diagnostics, management...
-

EMUCTV: Real world vs clinical trial outcomes in ccRCC patients eligible for adjuvant Pembrolizumab
November 7, 2026Assoc. Prof. Carlotta Palumbo (IT) alongside Dr. Luca Lambertini (IT) discuss Dr. Lambertini’s study: Real world vs clinical...
-

EMUCTV: Individualised prostate cancer early detection strategies in the genomic era
November 7, 2026Prof. Ros Eeles (GB) discusses individualised prostate cancer early detection strategies in the genomic era at EMUC26.
-

EMUCTV: EV-303, EV-304, VOLGA trials
November 7, 2026Dr. Benjamin Pradere (FR) discusses the EV-303, EV-304, VOLGA trials with Prof. Thomas Powles (GB) at EMUC26.
-

EMUCTV: How can we make TURBT better
November 6, 2026UROONCO BCa associate editor Dr. Roberto Contieri (IT) talks to Prof. Jonathan Aning (GB) on his lecture “How...
-

AI in GU cancers: From promise to clinical reality
November 6, 2026The Plenary Session ‘AI in GU cancers: Clinical partner or complex distraction?’ featured two keynote lectures, as well as...
-

EMUCTV: Radioligand therapy in mHSPC
November 6, 2026UROONCO PCa assoicate editor Prof. Claudia Kesch (DE) interviews Assoc. Prof. Matteo Bauckneht (IT) on radioligand therapy in...
-

Factors to consider for individualised advanced PCa care
November 6, 2026Plenary Session 1 “Individualised treatment in advanced prostate cancer” kickstarted with a clinical case presented by urologist Prof. Juan...

